TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of “Hold” by Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have earned a consensus rating of “Hold” from the six brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $6.00.

Several equities research analysts have recently commented on the stock. Wedbush restated an “outperform” rating and issued a $5.00 target price on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Wall Street Zen downgraded shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Friday, July 17th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in TScan Therapeutics by 7.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock worth $4,219,000 after acquiring an additional 168,540 shares during the last quarter. Aberdeen Group plc raised its position in TScan Therapeutics by 31.8% in the 4th quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock valued at $1,785,000 after purchasing an additional 430,421 shares during the last quarter. Renaissance Technologies LLC raised its position in TScan Therapeutics by 19.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,364,783 shares of the company’s stock valued at $1,378,000 after purchasing an additional 223,714 shares during the last quarter. Two Sigma Investments LP boosted its stake in TScan Therapeutics by 14.9% in the third quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock worth $763,000 after purchasing an additional 54,370 shares in the last quarter. Finally, Citadel Advisors LLC grew its holdings in shares of TScan Therapeutics by 78.4% during the third quarter. Citadel Advisors LLC now owns 390,747 shares of the company’s stock worth $711,000 after purchasing an additional 171,760 shares during the last quarter. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Trading Down 5.9%

Shares of TCRX opened at $0.85 on Friday. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.34. The stock has a market cap of $55.31 million, a PE ratio of -0.88 and a beta of 1.04. TScan Therapeutics has a 1 year low of $0.83 and a 1 year high of $2.57. The stock has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $1.06.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $2.50 million. On average, sell-side analysts predict that TScan Therapeutics will post -1.11 EPS for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.